Insider Buying Spurs Optimism for Oruka’s 2026 Phase‑1 Pipeline and Future Growth
Oruka insider buys 7,000 shares at $6.84‑$7.80 while selling higher‑priced shares, signaling confidence ahead of Phase‑1 data that could lift its negative‑P/E biotech into growth mode.
3 minutes to read